Omega-3s are effective as augmentation of mood stabilizers in bipolar depression, and in some cases, they improve negative symptoms in early schizophrenia. The research is vast, but we narrow down when and how to use omega-3s in real-world practice.

The straight facts on Loreev, a new extended-release formulation of lorazepam (Ativan).

Lybalvi hopes to lower the risk of weight gain on olanzapine by combining it with an opioid blocker (samidorphan). But how does it compare to generic options like metformin and naltrexone?

Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.

In the last five years, more psychotropics have gained approval through the FDA’s expedited pathways than the slow and cautious routes we’ve grown used to. These “fast-track” and “breakthrough therapy” approvals allow drugs to enter the market on the basis of more efficient (ie, smaller) clinical trials.

Most patients with bipolar disorder have cognitive complaints, but it’s a mistake to diagnose them all with ADHD, and a mistake to miss the genuine ADHD-bipolar comorbidity as well. Inside, a step-by-step guide to teasing apart the diagnoses.

Omega-3s are helpful for negative symptoms in schizophrenia, and this study suggests they may have metabolic benefits as well.

This new study is the first placebo-controlled trial to examine the long-term effects of an SSRI in bipolar disorder.